Heat Biologics
Scorpius Holdings Inc., via Scorpius BioManufacturing, is a CDMO accelerating biologic programs from development to clinic and beyond.
Launch date
Employees
Market cap
€5.5m
Enterprise valuation
€6m (Public information from Apr 2024)
Share price
€10 HTBX
Chapel Hill North Carolina (HQ)
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 3.0m | 3.0m | 2.0m | 6.0m | 7.0m | 20.6m | 35.1m |
| % growth | (50 %) | - | (33 %) | 200 % | 17 % | 194 % | 70 % |
| EBITDA | (19.2m) | (24.6m) | (32.9m) | (42.5m) | (34.5m) | - | - |
| % EBITDA margin | (639 %) | (820 %) | (1647 %) | (708 %) | (493 %) | - | - |
| Profit | (20.0m) | (26.0m) | (35.0m) | (43.0m) | (45.2m) | (22.2m) | (16.6m) |
| % profit margin | (667 %) | (867 %) | (1750 %) | (717 %) | (646 %) | (108 %) | (47 %) |
| EV / revenue | 1.1x | 4.2x | -8.6x | -2.4x | 3.3x | 0.3x | 0.2x |
| EV / EBITDA | -0.2x | -0.5x | 0.5x | 0.3x | -0.7x | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $250k | Seed | |
| N/A | $2.8m | Series A | |
| N/A | $5.1m | Growth Equity VC | |
| N/A | N/A | IPO | |
$7.5m | Post IPO Debt | ||
| N/A | $20.7m | Post IPO Equity | |
| N/A | $13.8m | Post IPO Equity | |
* | N/A | $7.0m | Post IPO Equity |
* | N/A | $2.3m | Post IPO Debt |
| Total Funding | €7.4m | ||
Recent News about Heat Biologics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Heat Biologics
Edit
ACQUISITION by Heat Biologics Apr 2022